Skip to main content

Table 2 Patient demographics and RA treatment history

From: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial

Characteristics

UPA 15 mg

(n=303)

ABA IVa

(n=309)

Age, mean ± SD

55.3 ± 11.4

55.8 ± 11.9

Female, n (%)

249 (82)

253 (82)

White, n (%)

288 (95)

285 (92)

Duration of RA diagnosis, mean ± SD

12.4 ± 9.5

11.8 ± 8.3

Number of prior bDMARDs received, n (%)

 1

206 (68)

202 (65)

 2

64 (21)

70 (23)

 ≥3

29 (10)

35 (11)

Number of prior TNF inhibitors received, n (%)

 0

40 (13)

36 (12)

 1

212 (70)

198 (64)

 2

38 (13)

64 (21)

 3

13 (4)

10 (3)

 ≥4

0

1 (0.3)

Concomitant csDMARDs at baseline, n (%)

 MTX alone

223 (74)

215 (70)

 MTX and other csDMARD

30 (10)

38 (12)

 csDMARD other than MTX

45 (15)

56 (18)

Oral steroid at baseline, n (%)

169 (56)

158 (51)

  1. aABA IV at day 1 and weeks 2, 4, 8, 12, 16, and 20 (<60 kg: 500 mg; 60–100 kg: 750 mg; >100 kg: 1000 mg). ABA abatacept, bDMARD biologic disease-modifying antirheumatic drug, csDMARD conventional synthetic disease-modifying antirheumatic drug, IV intravenous, MTX methotrexate, RA rheumatoid arthritis, SD standard deviation, TNF tumor necrosis factor, UPA upadacitinib